Gentiopicroside Alleviates Atherosclerosis by Suppressing Reactive Oxygen Species-Dependent NLRP3 Inflammasome Activation in Vascular Endothelial Cells via SIRT1/Nrf2 Pathway
Chinese Journal of Integrative Medicine · 2025-02 · 31 (2) · 118-130
DOI: 10.1007/s11655-024-4206-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chinese Journal of Integrative Medicine, online erschienen am 13.12.2024. Verfasst von Zhu-Qing Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Tianjin First Central Hospital, Tianjin, 300192, China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Reactive Oxygen Species, Iridoid Glucosides, NF-E2-Related Factor 2. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: To evaluate the protective effects of gentiopicroside (GPS) against reactive oxygen species (ROS)-induced NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome activation in endothelial cells, aiming to reduce atherosclerosis. METHODS: Eight-week-old male ApoE-deficient mice were randomly divided into 2 groups (n=10 per group): the vehicle group and the GPS treatment group. Both groups were fed a high-fat diet for 16 weeks. GPS (40 mg/kg per day) was administered by oral gavage to the GPS group, while the vehicle group received an equivalent volume of the vehicle solution. At the end of the treatment, blood and aortic tissues were collected for assessments of atherosclerosis, lipid profiles, oxidative stress, and molecular expressions related to NLRP3 inflammasome activation, ROS production, and apoptosis. Additionally, in vitro experiments on human aortic endothelial cells treated with oxidized low-density lipoprotein (ox-LDL) were conducted to evaluate the effects of GPS on NLRP3 inflammasome activation, pyroptosis, apoptosis, and ROS production, specifically examining the role of the sirtuin 1 (SIRT1)/nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. SIRT1 and Nrf2 inhibitors were used to confirm the pathway's role. RESULTS: GPS treatment significantly reduced atherosclerotic lesions in the en face aorta (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Tianjin First Central Hospital, Tianjin, 300192, China.
- The First Central Clinical School, Tianjin Medical University, Tianjin, 300070, China.
- Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, Hubei Province, 443003, China.
- School of Medicine, Nankai University, Tianjin, 300071, China.
- Department of Cardiology, Tianjin First Central Hospital, Tianjin, 300192, China. 5020200072@nankai.edu.cn.
Zitieren
APA
Li, Z. Q., Zhang, F., Li, Q., Wang, L., Sun, X. Q., Li, C., Yin, X. M., Liu, C. L., Wang, Y. X., Du, X. Y., & Lu, C. Z. (2025). Gentiopicroside Alleviates Atherosclerosis by Suppressing Reactive Oxygen Species-Dependent NLRP3 Inflammasome Activation in Vascular Endothelial Cells via SIRT1/Nrf2 Pathway. Chinese Journal of Integrative Medicine, 31(2), 118-130. https://doi.org/10.1007/s11655-024-4206-6
Vancouver
Li ZQ, Zhang F, Li Q, Wang L, Sun XQ, Li C, et al. Gentiopicroside Alleviates Atherosclerosis by Suppressing Reactive Oxygen Species-Dependent NLRP3 Inflammasome Activation in Vascular Endothelial Cells via SIRT1/Nrf2 Pathway. Chinese Journal of Integrative Medicine. 2025;31(2):118-130. doi:10.1007/s11655-024-4206-6
BibTeX
@article{Li2025,
author = {Li, Zhu-Qing and Zhang, Feng and Li, Qi and Wang, Li and Sun, Xiao-Qiang and Li, Chao and Yin, Xue-Mei and Liu, Chun-Lei and Wang, Yan-Xin and Du, Xiao-Yu and Lu, Cheng-Zhi},
title = {Gentiopicroside Alleviates Atherosclerosis by Suppressing Reactive Oxygen Species-Dependent NLRP3 Inflammasome Activation in Vascular Endothelial Cells via SIRT1/Nrf2 Pathway},
journal = {Chinese Journal of Integrative Medicine},
year = {2025},
volume = {31},
number = {2},
pages = {118--130},
doi = {10.1007/s11655-024-4206-6}
}
EUVIMED